Long-term cardiovascular disease risk after anthracycline and trastuzumab treatments in US breast cancer survivors

Although breast cancer survivors are at risk for cardiovascular disease (CVD) from treatment late effects, evidence to inform long-term and age-specific cardiovascular surveillance recommendations is lacking.